EPISODE · Nov 18, 2022 · 13 MIN
MP R Weekly Dose 138 — Elahere Gets Accelerated Approval; Zejula Use Restricted; Update for IUD System; Interchangeable Insulin Products; Panel Votes on Tenapanor
from MPR Weekly Dose
Newly approved gynecologic cancer treatment; Zejula has it's use restricted; intrauterine system use extended; a second insulin product is approved as a biosimilar to Lantus; and an FDA Advisory Committee take a vote on tenapanor.
Embed this episode
Ready to play
MP R Weekly Dose 138 — Elahere Gets Accelerated Approval; Zejula Use Restricted; Update for IUD System; Interchangeable Insulin Products; Panel Votes on Tenapanor
0:00
13:39
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 13 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on November 18, 2022.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!